Touchlight Appoints Will Downie to Propel Genetic Medicine Innovation

Touchlight, a global innovator in synthetic DNA technology, has announced the appointment of Will Downie as a key adviser. With over 30 years of experience in pharmaceutical and biotech industries, Downie brings invaluable leadership and strategic growth expertise to support Touchlight’s mission of advancing genetic medicines. His impressive career includes roles as CEO of Vectura Group and Argenta, along with a decade as Chief Commercial Officer at Catalent Inc., where he played a pivotal role in expanding its CDMO operations.

Expressing his enthusiasm, Downie said, “Touchlight’s groundbreaking synthetic DNA platform has the potential to revolutionize genetic medicine.” Founder Johnny Ohlson highlighted Downie’s deep understanding of the pharma services sector, emphasizing his value in scaling Touchlight’s innovative solutions. With its enzymatic DNA technology, the company aims to meet the growing demand for rapid and scalable genetic material production, essential for therapies and vaccines. Downie’s insights will further accelerate Touchlight’s impact on next-generation healthcare advancements.